financetom
Business
financetom
/
Business
/
Update: Supreme Court Reportedly Rejects American Airlines Appeal in JetBlue Antitrust Case
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Supreme Court Reportedly Rejects American Airlines Appeal in JetBlue Antitrust Case
Jun 30, 2025 10:40 AM

01:15 PM EDT, 06/30/2025 (MT Newswires) -- (Updates with American Airlines ( AAL ) response in the fifth paragraph.)

The US Supreme Court on Monday turned away a bid by American Airlines ( AAL ) to overturn a decision that found that its former partnership with JetBlue ( JBLU ) in the US Northeast violated antitrust law, multiple media outlets reported.

The partnership, called the "Northeast Alliance," allowed the two airlines to coordinate flights and share revenue in New York and Boston, the reports said.

The Justice Department sued in 2021, arguing the deal would reduce competition and hurt consumers by removing incentives for American Airlines ( AAL ) to lower prices. A lower court agreed with the Justice Department, and JetBlue ( JBLU ) ended the alliance in 2023, according to the reports.

American Airlines ( AAL ) appealed, claiming the decision went too far and could block future business partnerships that help competition. However, the 1st US Circuit Court upheld the ruling, and now the Supreme Court has declined to review it, the reports said.

"We're disappointed but appreciate the Supreme Court's consideration," American Airlines ( AAL ) told MT Newswires via email. The airline also said that the alliance was formed with the intention of boosting competition and giving customers more choices in the Northeast.

JetBlue ( JBLU ) didn't immediately reply to MT Newswires' request for comment.

Price: 11.20, Change: -0.08, Percent Change: -0.75

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sanofi, Regeneron Pharmaceuticals Receive Chinese Regulator's Approval for Dupixent as Chronic Obstructive Pulmonary Disease Treatment
Sanofi, Regeneron Pharmaceuticals Receive Chinese Regulator's Approval for Dupixent as Chronic Obstructive Pulmonary Disease Treatment
Oct 2, 2024
07:38 AM EDT, 09/27/2024 (MT Newswires) -- Sanofi ( SNY ) and Regeneron Pharmaceuticals ( REGN ) said Friday that China's National Medical Products Administration has approved Dupixent as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease, or COPD, characterized by raised blood eosinophils. The companies said the approval particularly covers patients who are under treatment...
Analysis-Mining industry struggles with valuation gap amid shift to copper
Analysis-Mining industry struggles with valuation gap amid shift to copper
Oct 2, 2024
LONDON (Reuters) - Leading mining companies are struggling to balance investor expectations for hefty returns with paying the necessary premiums to buy pure play copper companies as global demand for the metal sends valuations soaring. Big diversified miners including Rio Tinto, BHP Group ( BHP ) and Glencore ( GLCNF ), pressured by a slowdown in global economic growth and...
BMO on The Day Ahead in Canada
BMO on The Day Ahead in Canada
Oct 2, 2024
07:35 AM EDT, 09/27/2024 (MT Newswires) -- Canada's gross domestic product data for July and flash August at 8:30 a.m. ET Friday could have a major bearing on the size of the next rate cut by the country's central bank, said Bank of Montreal (BMO). Real GDP numbers for July and flash August will guide estimates for the quarter, noted...
Top Premarket Decliners
Top Premarket Decliners
Oct 2, 2024
07:42 AM EDT, 09/27/2024 (MT Newswires) -- Aytu BioPharma ( AYTU ) shares slumped 19% pre-bell Friday after the company reported weaker fiscal Q4 financial results. Fenbo Holdings ( FEBO ) shares retreated 17%, erasing Thursday's rally. enVVeno Medical (NVNO) shares fell 16% after pricing a $15 million public offering of common shares and pre-funded warrants. Telesis Bio ( TBIO...
Copyright 2023-2026 - www.financetom.com All Rights Reserved